Investment in Hoth Therapeutics, Inc	3 Months Ended
Mar. 31, 2018
Investment In Hoth Therapeutics Inc
Investment in Hoth Therapeutics, Inc.	Note 4. Investment in Hoth Therapeutics, Inc. On June 30, 2017 (the “Closing Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Hoth Therapeutics, Inc., a Nevada corporation (“Hoth”), for the purchase of an aggregate of 6,800,000 shares of common stock, par value $0.0001 (the “Shares”), of Hoth, for a purchase price of $675,000. The Company adopted the fair value option for this investment. There was no change in fair value for this investment during the three months ended March 31, 2018 (see Note 7).

Investment in Hoth Therapeutics, Inc

3 Months Ended

Mar. 31, 2018

Note 4. Investment in Hoth Therapeutics, Inc.

On June 30, 2017 (the “Closing Date”), the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Hoth Therapeutics, Inc., a Nevada corporation (“Hoth”), for the purchase of an aggregate of 6,800,000 shares of common stock, par value $0.0001 (the “Shares”), of Hoth, for a purchase price of $675,000. The Company adopted the fair value option for this investment. There was no change in fair value for this investment during the three months ended March 31, 2018 (see Note 7).